Boston-based biopharma company Yumanity Therapeutics announced last week that its drug candidate, YTX-7739, met its primary end points in a Phase 1b trial in patients with mild to moderate Parkinson’s disease.
A monoclonal antibody that binds to alpha-synuclein is advancing into a clinical trial after showing positive results in the preclinical phase. The compound, known as ABBV-0805, was developed in collaboration between AbbVie and BioArctic, a Swedish biopharma company that focuses on neurodegenerative diseases.
A hallmark of Parkinson’s disease is the presence of Lewy bodies—abnormal clumps of protein primarily made of alpha-synuclein—the reduction of which is hypothesized to stop or slow the development and progression of Parkinson’s and related diseases such as dementia with Lewy bodies and multiple system atrophy.
Researchers at the University of Utah tested more than 150,000 compounds in search of candidates that could reduce levels of alpha-synuclein, a protein that forms clumps and kills neurons, leading to neurodegenerative diseases like Parkinson’s disease and dementia with Lewy bodies.
In a new paper published in Movement Disorders, researchers for the first time established a link between the presence of misfolded alpha-synuclein and X-linked dystonia-Parkinsonism, also known as “Lubag.”
Biotech company Gain Therapeutics, Inc. announced positive results from an initial study of two Structurally Targeted Allosteric Regulators (STARs), GT-02287 and GT-02329, for the potential treatment of Parkinson’s and Gaucher disease. Using their Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) platform, Gain analyzes the 3D structure of proteins to identify new treatment targets in neurodegenerative disorders.
Previous research has demonstrated that alpha-synuclein can damage mitochondria, the organelle responsible for cellular energy production, contributing to the progression of Parkinson’s disease. New research from the State University of New York at Buffalo sheds light on the previously undiscovered ways that alpha-synuclein affects mitochondria.
Annovis Bio, Inc., has completed a two-part Phase 2a study of ANVS401 (also known as Posiphen), its investigational treatment for Alzheimer’s and Parkinson’s disease. ANVS401 works by inhibiting the formation of beta-amyloid and tau in Alzheimer’s and alpha-synuclein in Parkinson’s, which differs from other drugs that aim to clear these compounds after they’ve formed.
There are currently no treatments available for multiple system atrophy (MSA), a rare and fatal neurodegenerative disorder caused by the accumulation of alpha-synuclein in the brain. MSA causes problems with movement, balance, and the control of some involuntary bodily functions such as blood pressure and bowel and bladder function. Last month, Alterity Therapeutics published promising results in Movement Disorders of ATH434 in a mouse model of the disease.
Biopharmaceutical company Seelos Therapeutics in conjunction with researchers at Duke University School of Medicine announced promising results for an epigenome-editing therapy designed to reduce alpha-synuclein levels.